Местные рецидивы рака молочной железы после органосохраняющего лечения: место онкопластических резекций и факторы риска

DOI: https://doi.org/10.29296/25877305-2021-08-01
Скачать статью в PDF
Номер журнала: 
8
Год издания: 
2021

А.Д. Зикиряходжаев(1)–3, доктор медицинских наук, Е.А. Рассказова(1), кандидат медицинских
наук, Д.Ф. Омарова(2), Ф.С. Хугаева(2), Д.Р. Ортабаева(1), А.В. Трегубова(1), И.В. Решетов(2), академик РАН,
доктор медицинских наук, профессор, А.Д. Каприн(3, 4), академик РАН, доктор медицинских наук, профессор
(1)Московский научно-исследовательский онкологический институт им. П.А. Герцена – филиал Национального
медицинского исследовательского центра радиологии Минздрава России (2)Первый МГМУ им. И.М. Сеченова
Минздрава России (Сеченовский Университет) (3)Российский университет дружбы народов, Москва (4)Национальный
медицинский исследовательский центр радиологии Минздрава России, Обнинск E-mail: jiomarova@gmail.com

Рак молочной железы (РМЖ) занимает первое место в структуре онкологической заболеваемости у женщин. Комплексный подход к лечению больных РМЖ, включающий высокоэффективные варианты лекарственного лечения и послеоперационную лучевую терапию, позволяет хирургам выполнять операции различного объема – от туморэктомий до радикальных мастэктомий с реконструкцией молочных желез. Выполнение органосохраняющих операций (ОСО) в комбинированном/комплексном лечении РМЖ приводит к равным показателям безрецидивной и общей выживаемости в сравнении с мастэктомией, несмотря на более высокую частоту местных рецидивов. Широкое распространение в течение последних десятилетий онкопластических резекций, объединяющих в себе принципы онкологической безопасности и эстетической хирургии, позволили расширить показания к органосохраняющему лечению РМЖ. Сегодня вопросы онкологической безопасности выполнения ОСО как обычных (туморэктомии, лампэктомии, квадрантэктомии), так и онкопластических резекций не теряют своей актуальности. Благодаря персонализированному подходу к лечению РМЖ интересным остается вопрос определения предикторов местного рецидива после ОСО. В данной статье приведен обзор литературы, отражающий онкологические результаты проведения ОСО больным РМЖ, а также факторы, влияющие на частоту местного рецидивирования.

Ключевые слова: 
онкология
рак молочной железы
органосохраняющее лечение
онкопластические резекции
местные рецидивы
гормонотерапия
резекция молочной железы

Для цитирования
А.Д. Зикиряходжаев, Е.А. Рассказова, Д.Ф. Омарова, Ф.С. Хугаева, Д.Р. Ортабаева, А.В. Трегубова, И.В. Решетов, А.Д. Каприн Местные рецидивы рака молочной железы после органосохраняющего лечения: место онкопластических резекций и факторы риска . Врач, 2021; (8): 5-10 https://doi.org/10.29296/25877305-2021-08-01


It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

Список литературы: 
  1. The Global Burden of Disease Cancer. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability,and Disability-Adjusted Life-Years for 29 Cancer Groups,1990 to 2017. A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncology. 2019; 5 (12): 1749–69. DOI: 10.1001/jamaoncol.2019.2996
  2. Каприн А.Д., Старинский В.В., Петрова Г.В. Состояние онкологической помощи населению России в 2018 году. М.: РИИС ФИАН, 2019 [Kaprin A.D., Starinskii V.V., Petrova G.V. Sostoyanie onkologicheskoi pomoshchi naseleniyu Rossii v 2018 godu. M.: RIIS FIAN, 2019 (in Russ.)].
  3. Lakhtakia R. A Brief History of Breast Cancer: Part I: Surgical domination reinvented. Sultan Qaboos Univ Med J. 2014; 14 (2): e166-9.
  4. Payne W.S., Taylor W.F., Khonsari S. et al. Surgical Treatment of Breast Cancer. Trends and Factors Affecting Survival. Arch Surg. 1970; 101 (2): 105–13. DOI: 10.1001/archsurg.1970.01340260009002
  5. Lukong K.E. Understanding breast cancer – The long and winding road. BBA clinical. 2017; 7: 64–77. DOI: 10.1016/j.bbacli.2017.01.001
  6. Cotlar A.M., Dubose J.J., Rose D.M. History of surgery for breast cancer: radical to the sublime. Curr Surg. 2003; 60 (3): 329–37. DOI: 10.1016/S0149-7944(02)00777-8
  7. Fisher B., Bauer M., Margolese R. et al. Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. N Engl J Med. 1985; 312 (11): 665–73. DOI: 10.1056/NEJM198503143121101
  8. Fisher B., Redmond C., Poisson R. et al. Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without radiation in the treatment of breast cancer. N Engl J Med. 1989; 320 (13): 822–8. DOI: 10.1056/NEJM198903303201302
  9. Fisher B., Anderson S., Bryant J. et al. Twenty-Year Follow-up of a Randomized Trial Comparing Total Mastectomy, Lumpectomy, and Lumpectomy plus Irradiation for the Treatment of Invasive Breast Cancer. N Engl J Med. 2002; 347 (16): 1233–41. DOI: 10.1056/NEJMoa022152
  10. Veronesi U., Banfi A., Saccozzi R.et al. Conservative treatment of breast cancer. A Trial in Progress at the Cancer Institute of Milan. Cancer. 1977; 39 (6 Suppl): 2822–6. DOI: 10.1002/1097-0142(197706)39:63.0.co;2-
  11. #Veronesi U., Salvadori R., Luini A. et al. Conservative Treatment of Early Breast Cancer. Long-term results of 1232 cases treated with quadrantectomy, axillary dissection, and radiotherapy. Ann Surg. 1990; 211 (3): 250–9.
  12. Arriagada R., Lê M.G., Rochard F. et al. Conservative Treatment Versus Mastectomy in Early Breast Cancer: Patterns of Failure With 15 Years of Follow-Up Data. J Clin Oncol. 1996; 14 (5): 1558–64. DOI: 10.1200/JCO.1996.14.5.1558
  13. Litière S., Werutsky G., Fentiman I.S. et al. Breast conserving therapy versus mastectomy for stage I–II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial. Lancet Oncol. 2012; 13 (4): 412–9. DOI: 10.1016/S1470-2045(12)70042-6
  14. Black D.M., Hunt K.K., Mittendorf E.A. Long term outcomes reporting the safety of breast conserving therapy compared to mastectomy: 20-year results of EORTC 10801. Gland Surg. 2013; 2 (3): 120–3. DOI: 10.3978/j.issn.2227-684X.2013.06.01
  15. Scholl S.M., Fourquet A., Asselain B. et al. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: Preliminary results of a randomised trial: S6. Eur J Cancer. 1994; 30A: 645–52. DOI: 10.1016/0959-8049(94)90537-1
  16. Fisher B., Brown A., Mamounas E. et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol. 1997; 15 (7): 2483–93. DOI: 10.1200/JCO.1997.15.7.2483
  17. Mauriac L., MacGrogan G., Avril A. et al. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonié Bordeaux Groupe Sein (IBBGS). Ann Oncol. 1999; 10 (1): 47–52. DOI: 10.1023/a:1008337009350
  18. Levy A., Borget I., Bahri M. et al. Loco-regional Control After Neo-adjuvant Chemotherapy and Conservative Treatment for Locally Advanced Breast Cancer Patients. Breast J. 2014; 20 (4): 381–7. DOI: 10.1111/tbj.12277
  19. Cho J.H., Park J.M., Park H.S. et al. Oncologic safety of breast-conserving surgery compared to mastectomy in patients receiving neoadjuvant chemotherapy for locally advanced breast cancer. J Surg Oncol. 2013; 108 (8): 531–6. DOI: 10.1002/jso.23439
  20. Sun Y., Liao M., He L. et al. Comparison of breast-conserving surgery with mastectomy in locally advanced breast cancer after good response to neoadjuvant chemotherapy: A PRISMA-compliant systematic review and meta-analysis. Medicine (Baltimore). 2017; 96 (43): e8367. DOI: 10.1097/MD.0000000000008367
  21. Bertozzi N., Pesce M., Santi P.L. et al. Oncoplastic breast surgery: comprehensive review. Eur Rev Med Pharmacol Sci. 2017; 21 (11): 2572–85.
  22. Santos G., Urban C., Edelweiss M.I. et al. Long-Term Comparison of Aesthetical Outcomes After Oncoplastic Surgery and Lumpectomy in Breast Cancer Patients. Ann Surg Oncol. 2015; 22 (8): 2500–8. DOI: 10.1245/s10434-014-4301-6
  23. Doğru V., Yaprak M., Durmaz E. et al. Oncoplastic approach to excisional breast biopsies: a randomized controlled, phase 2a trial. Breast Cancer. 2019; 26 (1): 84–92. DOI: 10.1007/s12282-018-0892-2
  24. Gabka C.J., Baumeister R.G., Maiwald G. Advancements of breast conserving therapy by onco-plastic surgery in the management of breast cancer. Anticancer Res. 1998; 18 (3C): 2219–24.
  25. Weber W.P., Soysal S.D., Fulco I. et al. Standardization of oncoplastic breast conserving surgery. Eur J Surg Oncol. 2017; 43 (7): 1236–43. DOI: 10.1016/j.ejso.2017.01.006
  26. Yiannakopoulou E.C., Mathelin C. Oncoplastic breast conserving surgery and oncological outcome: Systematic review. Eur J Surg Oncol. 2016; 42 (5): 625–30. DOI: 10.1016/j.ejso.2016.02.002
  27. De La Cruz L., Blankenship S.A., Chatterjee A. et al. Outcomes After Oncoplastic Breast-Conserving Surgery in Breast Cancer Patients: A Systematic Literature Review. Ann Surg Oncol. 2016; 23 (10): 3247–58. DOI: 10.1245/s10434-016-5313-1
  28. Clough K.B., van la Parra R.F.D., Thygesen H.H. et al. Long-term Results After Oncoplastic Surgery for Breast Cancer. A 10-year Folow-up. Ann Surg. 2017; 268 (1): 165–71. DOI: 10.1097/SLA.0000000000002255
  29. Kaviani A., Safavi A., Mohammadzadeh N. et al. Oncoplastic surgery in breast conservation: a prospective evaluation of the patients, techniques, and oncologic outcomes. Am J Surg. 2014; 208 (5): 727–34. DOI: 10.1016/j.amjsurg.2014.04.005
  30. Niinikoski L., Leidenius M.H.K., Vaara P. et al. Resection margins and local recurrences in breast cancer: Comparison between conventional and oncoplastic breast conserving surgery. Eur J Surg Oncol. 2014; 45 (6): 976–82. DOI: 10.1016/j.ejso.2019.02.010
  31. Acea-Nebril B., Cereijo-Garea C., Garcia-Novoa A. et al. The role of oncoplastic breast reduction in the conservative management of breast cancer: Complications, survival, and quality of live. J Surg Oncol. 2017; 115 (6): 679–86. DOI: 10.1002/jso.24550
  32. Mansell J., Weiler-Mithoff E., Stallard S. et al. Oncoplastic breast conservation surgery is oncologically safe when compared to wide local excision and mastectomy. Breast. 2017; 32: 179–85. DOI: 10.1016/j.breast.2017.02.006
  33. Kosasih S., Tayeh S., Mokbel K. et al. Is oncoplastic breast conserving surgery oncologically safe? A meta-analysis of 18,103 patients. Am J Surg. 2020; 220 (2): 385–92. DOI: 10.1016/j.amjsurg.2019.12.019
  34. Arvold N.D., Taghian A.G., Niemierko A. et al. Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy. J Clin Oncol. 2011; 29 (29): 3885–91. DOI: 10.1200/JCO.2011.36.1105
  35. Aalders K.C., Postma E.L., Strobbe L.J. et al. Contemporary Locoregional Recurrence Rates in Young Patients With Early-Stage Breast Cancer. J Clin Oncol. 2016; 34 (18): 2107–14. DOI: 10.1200/JCO.2015.64.3536
  36. Miles R.C., Gullerud R.E., Lohse C.M. et al. Local Recurrence after Breast-Conserving Surgery: Multivariable Analysis of Risk Factors and the Impact of Young Age. Ann Surg Oncol. 2011; 19 (4): 1153–9. DOI: 10.1245/s10434-011-2084-6
  37. Maishman T., Cutress R.I., Hernandez A. et al. Local Recurrence and Breast Oncological Surgery in Young Women With Breast Cancer: The POSH Observational Cohort Study. Ann Surg. 2017; 266 (1): 165–72. DOI: 10.1097/SLA.0000000000001930
  38. Haffty B.G., Harrold E., Khan A.J. et al. Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status. Lancet. 2002; 359 (9316): 1471–7. DOI: 10.1016/S0140-6736(02)08434-9
  39. van den Broek A.J., Schmidt M.K., van’t Veer L.J. et. al. Prognostic Impact of Breast-Conserving Therapy Versus Mastectomy of BRCA1/2 Mutation Carriers Compared With Noncarriers in a Consecutive Series of Young Breast Cancer Patients. Ann Surg. 2019; 270 (2): 364–72. DOI: 10.1097/SLA.0000000000002804
  40. Huang X., Cai X.Y., Liu J.Q. et al. Breast-conserving therapy is safe both within BRCA1/2 mutation carriers and noncarriers with breast cancer in the Chinese population. Gland Surg. 2020; 9 (3): 775–87. DOI: 10.21037/gs-20-531
  41. Kirova Y.M., Savignoni A., Sigal-Zafrani B. et al. Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature. Breast Cancer Res Treat. 2010; 120 (1): 119–26. DOI: 10.1007/s10549-009-0685-6
  42. Veronesi U., Marubini E., Del Vecchio M. et al. Local recurrences and distant metastases after conservative breast cancer treatments: partly independent events. J Natl Cancer Inst. 1995; 87 (1): 19–27. DOI: 10.1093/jnci/87.1.19
  43. Семиглазов В.Ф., Семиглазов В.В., Клецель А.Е. Неинвазивные и инвазивные опухоли молочной железы. СПб, 2006 [Semiglazov V.F., Semiglazov V.V., Kletsel’ A.E. Neinvazivnye i invazivnye opukholi molochnoi zhelezy. SPb, 2006 (in Russ.)].
  44. Antonini N., Jones H., Horiot J.C. et al. Effect of age and radiation dose on local control after breast conserving treatment: EORTC trial 22881-10882. Radiother Oncol. 2007; 82 (3): 265–71. DOI: 10.1016/j.radonc.2006.09.014
  45. Moran M.S., Schnitt S.J., Giuliano A.E. et al. Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. Int J Radiat Oncol Biol Phys. 2014; 88 (3): 553–64. DOI: 10.1016/j.ijrobp.2013.11.012
  46. Lin J., Lin K.J., Wang Y.F. et al. Association of surgical margins with local recurrence in patients undergoing breast-conserving surgery after neoadjuvant chemotherapy. BMC Cancer. 2020; 20 (1): 451. DOI: 10.1186/s12885-020-06955-6
  47. Holleczek B., Stegmaier C., Radosa J.C. et al. Risk of loco-regional recurrence and distant metastases of patients with invasive breast cancer up to ten years after diagnosis – results from a registry-based study from Germany. BMC Cancer. 2019; 19 (1): 520. DOI: 10.1186/s12885-019-5710-5
  48. Ignatov A., Eggemann H., Burger E. et al. Patterns of breast cancer relapse in accordance to biological subtype. J Cancer Res Clin Oncol. 2018; 144 (7): 1347–55. DOI: 10.1007/s00432-018-2644-2
  49. Valachis A., Mamounas E.P., Mittendorf E.A. et al. Risk factors for locoregional disease recurrence after breast-conserving therapy in patients with breast cancer treated with neoadjuvant chemotherapy: An international collaboration and individual patient meta-analysis. Cancer. 2018; 124 (14): 2923–30. DOI: 10.1002/cncr.31518
  50. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Darby S, McGale P, Correa C. et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011; 378 (9804): 1707–16. DOI: 10.1016/S0140-6736(11)61629-2
  51. Wickberg Å., Magnuson A., Holmberg L. et al. Influence of the subtype on local recurrence risk of breast cancer with or without radiation therapy. Breast. 2018; 42: 54–60. DOI: 10.1016/j.breast.2018.08.097
  52. Anderson W.F., Chen B.E., Jatoi I. et al. Effects of estrogen receptor expression and histopathology on annual hazard rates of death from breast cancer. Breast Cancer Res Treat. 2006; 100 (1): 121–6. DOI: 10.1007/s10549-006-9231-y